Richard Zwicky spoke with Dr. Joseph Tucker, CEO of Enveric Biosciences about their development of non-hallucinogenic neuroplastogens, inspired by psychedelic research, to stimulate neuroplasticity for therapeutic benefits. Listen to Podcast…
Read More
In the shadow of headlines about the mental health crisis and the limits of current psychiatric care, one small biotech is making quiet but meaningful progress. Enveric Biosciences (NASDAQ: ENVB)…
Read More
New data confirms Enveric’s lead neuroplastogen acts on a serotonin receptor tied to depression, Parkinson’s, and migraine. Enveric Biosciences has announced that EB-003, its oral, non-hallucinogenic neuroplastogen, also acts as…
Read More
In an industry defined by bold ideas and even bolder challenges, Enveric Biosciences (NASDAQ: ENVB) is quietly making a case to lead the next generation of neuropsychiatric drug innovation. On…
Read More
With U.S. Patent No. 12,187,679 now granted, Enveric Biosciences has secured more than intellectual property—it’s staked a claim on the future of neurotherapeutics. The Cambridge-based biotech firm announced this week…
Read More
The psychedelic industry stands at the cusp of a transformative era, propelled by the development of next-generation molecules with the potential to be more effective treatments for a host of…
Read More
In a significant development for mental health treatments, Enveric Biosciences (NASDAQ: ENVB) has secured its first U.S. patent for a novel series of compounds that could transform how we approach neuropsychiatric disorders. The company’s…
Read More
Enveric Biosciences has secured its first U.S. patent for the EVM401 Series, a novel collection of non-hallucinogenic, mescaline-derived compounds. These compounds are designed to address addiction, ADHD anxiety, and other…
Read More
New patent for mescaline derivative compounds broadens Enveric's potential to develop neuroplastogen therapeutics for addiction and neuropsychiatric disorders CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a…
Read More
The treatment landscape for joint diseases like osteoarthritis and rheumatoid arthritis is poised for a significant breakthrough, thanks to an innovative licensing deal between Enveric Biosciences and Restoration Biologics. The…
Read More
